Sara M. Tolaney, MD, MPH, discusses what is currently known about mechanisms of resistance in metastatic HR-positive breast cancer after receiving a CDK4/6 inhibitor with endocrine therapy, highlights factors that impact one’s choice for additional therapy after progression, and remarks on what she looks forward to as additional studies further explore the potential for CDK4/6 inhibition in patients with breast cancer.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
